SEC Form 4 · accession 0001390478-16-000128
SELLAS Life Sciences Group, Inc. · SLS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sanford Hillsberg
Director
Period of report
Jul 14, 2016
Accepted (ET)
Jul 18, 2016 · 6:15 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001390478
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1,F2 | $0.41 | Jul 14, 2016 | A | 100,000 | A | — | Jul 14, 2026 | Common Stock | 100,000 | 100,000 | D |
Explanation of responses
- F1Granted pursuant to the Issuer's 2016 Incentive Plan.
- F2This stock option will vest and become exercisable in equal, quarterly installments over one year, beginning three months from July 14, 2016, such that the option will be fully exercisable as of July 14, 2017.